Kisspeptin
Kisspeptin is the master regulator of human reproductive biology. A naturally occurring neuropeptide family that signals your pituitary to release the hormones that govern fertility, libido, and long-term endocrine health. This page summarizes what the published literature reports about kisspeptin's role in the reproductive axis, what has been studied in humans, and where the evidence stops.
Research status. Kisspeptin is a research peptide. It is not FDA approved for any indication discussed on this page. Kisspeptin-10 remains on the FDA's Category 2 list of bulk drug substances that may present significant safety risks, added 29 September 2023, and cannot lawfully be compounded under Section 503A. Kisspeptin is on the World Anti-Doping Agency (WADA) Prohibited List under S2 (Peptide Hormones and Related Substances) and is prohibited in males at all times, in and out of competition. Female athletes should verify current status with their governing body.
-Photoroom.png)
Overview
Kisspeptin sits at the top of the reproductive axis. When your brain releases it, your hypothalamus releases GnRH, your pituitary releases LH and FSH, and your gonads produce testosterone or estrogen in response. It is the switch that turns the whole cascade on.
That position matters. Most hormone therapies act downstream, replacing the hormones your body has stopped making. Kisspeptin works further up the chain. It asks your own system to respond, rather than bypassing it.
Low testosterone with preserved pituitary capacity. Hypothalamic amenorrhea. Fertility work. Libido complaints that track with endocrine signals rather than lifestyle or relationship factors. It is a precision tool. It is not a general wellness add-on.
.jpg)
CHEMICAL STRUCTURE & PROPERTIES
- Molecular Formula (KP-54): C₂₅₈H₄₀₁N₇₉O₇₈
- Molecular Weight (KP-54): 5,857.41 Daltons
- Sequence (KP-10): Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂
- Conserved Motif: C-terminal RFamide (Arg-Phe-NH₂)
- CAS Number (KP-10): 374675-21-5
- Half-life (KP-54): Approximately 28 minutes in plasma following IV administration
- Half-life (KP-10): Approximately 4 minutes in plasma
- Stability: Lyophilised powder; store at 2°C to 8°C before reconstitution
Mechanism of Action
Areas Investigated in
the Research Literature
.jpg)
Current Clinical Evidence
Safety Considerations
Regulatory Status and Legal Considerations
Regulatory information current as of 28 August 2026. This is a summary, not legal or medical advice, and status can change.
FDA Status
- Not FDA approved for the indications discussed on this page
- No regulatory approval from any major health authority for the uses described here
- Classified as a research peptide with no approved medical use
WADA Status
- Category: S2 — Peptide Hormones and Related Substances (prohibited at all times)
- Rationale: Classification as a peptide hormone affecting the reproductive axis
- Athletic Use: Prohibited in males, in and out of competition, under WADA S2
- Detection: Urine and blood testing available for anti-doping purposes
Legal Availability
- Research use of kisspeptin is legal in the United States
- Not approved by the FDA for any therapeutic use
.jpg)
Conclusion
What the evidence supports.
Kisspeptin occupies an unusual position in reproductive endocrinology. It acts upstream of the therapies most commonly used, asking the body's own axis to respond rather than replacing its output. Human studies have reported LH release in men with low testosterone, ovulation induction in women with hypothalamic amenorrhea, and activity in brain regions associated with arousal.
The evidence remains early. Study populations are small, long-term safety data is absent, and dosing has not been standardized. No regulatory authority has approved kisspeptin for any of the uses described above. This page summarizes that research and nothing further.
KISSPEPTIN SCIENTIFIC
DATA SUMMARY
About this library
This library is published for education. It summarizes published research on compounds studied in this field. Many have no approved medical use, and several cannot lawfully be compounded in the United States. The presence of a page here does not mean Paragon offers that compound. Nothing on these pages is an offer to treat.
This page is general education about a compound studied in this field. Nothing here is medical advice, a recommendation, or an offer to prescribe or supply. A page appearing in this library does not mean Paragon Sports Medicine offers that compound.
Disclaimer: This information is provided for educational and research purposes only and does not constitute medical advice. Kisspeptin is not approved by the FDA, EMA, or any major regulatory authority for therapeutic use. All clinical data referenced herein is drawn from published peer-reviewed research. Kisspeptin is explicitly listed on the WADA Prohibited List under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) effective January 2024 and is prohibited in males both in- and out-of-competition. Athletes must not use kisspeptin in any competitive sport context. Patients and researchers should consult with qualified healthcare providers and ensure compliance with applicable regulations before considering any use of kisspeptin.
Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Many peptides described here are not FDA approved for the uses discussed, and some cannot lawfully be compounded in the United States. Nothing on this page is medical advice or a recommendation for any individual. Whether any therapy is appropriate depends on your history, your laboratory results, and a clinical evaluation. Individual results vary. This page is published for education. Use of this site does not create a physician-patient relationship.